Stay updated on PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Sign up to get notified when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.

Latest updates to the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page
- ChecktodayChange DetectedAn HTML error page was added, making the study record unavailable. Several core content sections and sponsor/IPD-related items were removed from the page, reducing the information available about the study.SummaryDifference17%

- Check8 days agoNo Change Detected
- Check15 days agoChange DetectedThe page revision label was updated from v3.6.3 to v3.6.4. This indicates an internal update to the page's metadata rather than any changes to the study content.SummaryDifference0.0%

- Check22 days agoNo Change Detected
- Check37 days agoChange DetectedThe page's revision label was updated from v3.6.2 to v3.6.3, indicating a new published revision of the record. This appears to be a small, internal version update with no visible changes to the study details or data.SummaryDifference0.0%

- Check44 days agoChange DetectedThe page's revision label was updated from v3.6.0 to v3.6.2, signaling a newer software patch for the study record; there are no described content changes in this update.SummaryDifference0.0%

- Check58 days agoChange DetectedNew help/navigation sections were added (How to Read a Study Record, Common Questions, How to Join a Study) and the Intervention/Treatment section was updated; the heading was normalized from 'Intervention / Treatment' to 'Intervention/Treatment' and the revision tag updated to v3.6.0 from v3.5.5. A note states that no participants are being recruited anymore, indicating enrollment is closed.SummaryDifference0.3%

- Check65 days agoChange DetectedThe page shows a new revision tag (v3.5.5) replacing the previous v3.5.4. This indicates a minor update to the page.SummaryDifference0.0%

Stay in the know with updates to PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo
Enter your email address, and we'll notify you when there's something new on the PD-L1+ NSCLC Clinical Trial: Pembrolizumab Combo page.